Depressive Symptoms, Systemic Inflammation, and Survival Among Patients With Head and Neck Cancer

Elizabeth Cash,Christy Albert,Iona Palmer,Baylee Polzin,Alyssa Kabithe,Devaughn Crawford,Jeffrey M. Bumpous,Sandra E. Sephton

DOI: https://doi.org/10.1001/jamaoto.2024.0231

2024-03-28

JAMA Otolaryngology–Head & Neck Surgery

Abstract:Importance Patients with head and neck cancer experience high rates of depression. Depression and systemic inflammation have been found to be associated in numerous cancer types, often independently from disease status. Depression-related inflammation may elevate the risks for poor tumor response to treatment and early mortality, and comprises a mechanism by which depression is associated with survival in head and neck cancer. Objective To assess mediation pathways incorporating pretreatment depressive symptoms, pretreatment inflammation, and tumor response posttreatment on overall survival among patients with head and neck cancer. Design, Setting, and Participants This was a prospective observational cohort study of patients with head and neck cancer treated in a single multidisciplinary head and neck cancer clinic from May 10, 2013, to December 30, 2019, and followed up for 2 years. Data analysis was performed from June 29, 2022, to June 23, 2023. Exposures Patient-reported depressive symptoms using the Patient Health Questionnaire−9 item (PHQ−9) at treatment planning; pretreatment hematology workup for systemic inflammation index (SII) score; and clinical data review for tumor response (complete vs incomplete) and overall survival. Main Outcomes Two-year overall survival. Results The total study cohort included 394 patients (mean [SD] age, 62.5 [11.5] years; 277 [70.3%] males) with head and neck cancer. Among 285 patients (72.3%) who scored below the clinical cutoff for depression on the PHQ−9, depressive symptoms were significantly associated with inflammation (partial r , 0.168; 95% CI, 0.007-0.038). In addition, both depression and inflammation were associated with early mortality (PHQ−9: hazard ratio [HR], 1.04; 95% CI, 1.02-1.07; SII: HR, 1.36; 95% CI, 1.08-1.71). The depression-survival association was fully mediated by inflammation (HR, 1.28; 95% CI, 1.00-1.64). Depressive symptoms were also associated with poorer tumor response (odds ratio, 1.05; 95% CI, 1.01-1.08), and the depression-survival association was partially mediated by tumor response (HR, 9.44; 95% CI, 6.23-14.32). Systemic inflammation was not associated with tumor response. Conclusions In this cohort study, systemic inflammation emerged as a novel candidate mechanism of the association of depression with mortality. Tumor response partially mediated effects of depression on mortality, replicating prior work. Thus, depression stands out as a highly feasible target for renewed clinical attention. Even mild symptoms of depression during the treatment-planning phase may be associated with higher systemic inflammation in addition to poorer tumor response to treatment and survival outcomes; therefore, depression should be clinically addressed.

surgery,otorhinolaryngology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the relationship among depression, systemic inflammation and survival rate, especially in patients with head and neck cancer. Specifically, the study attempts to answer the following questions:

1. **Is the association between depression and 2 - year overall survival rate mediated by systemic inflammation and tumor treatment response?**
- The study hypothesizes that in patients with head and neck cancer, there is an association between pre - treatment depressive symptoms and the subsequent 2 - year overall survival rate, and this association may be mediated by two biological pathways: systemic inflammation and tumor response to treatment.

2. **Does systemic inflammation significantly affect tumor response to treatment?**
- The study hypothesizes that a higher level of systemic inflammation is associated with a poorer tumor treatment response.

### Main findings

- **Relationship between depression and survival rate**:
- There is a significant association between depressive symptoms and 2 - year overall survival rate (HR = 1.04, 95% CI: 1.02 - 1.07).
- This association is fully mediated by systemic inflammation (HR = 1.28, 95% CI: 1.00 - 1.64) and partially mediated by tumor treatment response (HR = 9.44, 95% CI: 6.23 - 14.32).

- **Relationship between systemic inflammation and survival rate**:
- There is a significant association between the systemic inflammation index (SII) and 2 - year overall survival rate (HR = 1.36, 95% CI: 1.08 - 1.71).
- However, there is no significant association between systemic inflammation and tumor treatment response (OR = 1.32, 95% CI: 0.99 - 1.76).

### Conclusions

The results of this study indicate that even mild depressive symptoms may be associated with a higher level of systemic inflammation, a poorer tumor treatment response and a lower survival rate. Therefore, depression should be regarded as an important clinical concern, especially during the treatment planning stage for patients with head and neck cancer. These findings emphasize the importance of early identification and management of depression during the cancer treatment process.

### Formula summary

- **Hazard Ratio (HR)**:
\[
HR_{\text{depressive symptoms}} = 1.04\quad(95\%\text{ CI}: 1.02 - 1.07)
\]
\[
HR_{\text{systemic inflammation}} = 1.36\quad(95\%\text{ CI}: 1.08 - 1.71)
\]
\[
HR_{\text{tumor response}} = 9.44\quad(95\%\text{ CI}: 6.23 - 14.32)
\]

- **Mediation effect analysis**:
\[
HR_{\text{depressive symptoms through systemic inflammation}} = 1.28\quad(95\%\text{ CI}: 1.00 - 1.64)
\]

These formulas show the statistical relationships among depression, systemic inflammation and survival rate, providing important clues for understanding how depression affects the prognosis of patients with head and neck cancer.